• darkblurbg

    Towards a cure for type 1 diabetes

    Antigen based therapies
    Medical Technology
    Stem Cells

  • Diabetes

    More than 400 million people worldwide suffer from diabetes. 10-20% have an autoimmune form of the disease where the immune system attacks and destroys the insulin-producing beta cells. Autoimmune diabetes is a chronic disease and there is currently no cure.

  • Product Development

    Diamyd Medical develops the diabetes vaccine Diamyd®, based on the exclusively licensed GAD molecule. The Company’s licensed technologies GABA and Gliadin also have the potential to become key pieces of the puzzle to prevent, treat or cure autoimmune diabetes.

  • Clinical Trials

    The development of Diamyd Medical’s licensed technologies for GAD, GABA and Gliadin, in combination or with other substances with various mechanisms of action, is carried out in clinical trials and preclinical studies. Six clinical trials are currently ongoing.


Diamyd Medical is a Swedish diabetes company active in the field of pharmaceutical development
The share is listed on Nasdaq Stockholm First North (ticker: DMYD B)

Read More
  Financial Statement, October 2016

Dear Shareholders

We have now closed the books on an intensive and exciting fiscal year – a year in which my role as the new CEO of Diamyd Medical was characterized by a focus on strategy and business development. My goal has been to further strengthen the company’s licensing possibilities and thus the core of our business model.

So what have we accomplished during the year and how will the results of this work benefit you as a shareholder? To achieve the goal of strengthening our licensing offering, we focused on three stages: 1) evaluating...

Opinion makers in the field clearly advocate studies that are in line with Diamyd Medical’s development strategy.
Ulf Hannelius, President and CEO